Biosimilars Battle: Celltrion’s Remsima Takes On J&J’s Remicade In Korea
This article was originally published in PharmAsia News
Executive Summary
Although still early after launch, Celltrion is battling J&J in the Korean market with a biosimilar of Remicade. If the war of words is any indication, things are just starting to heat up.